Anti-Respiratory Syncytial Virus (RSV)
Anti-Respiratory Syncytial Virus (RSV)
Product No.: F654
- -
- -
Clone RSV-96217 Target Respiratory Syncytial Virus Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names RSV, Orthopneumovirus Isotype Mouse IgG2a Applications ELISA , IF , N |
- -
- -
Antibody DetailsProduct DetailsReactive Species Respiratory Syncytial Host Species Mouse Product Concentration 100 μg/ml Purity >90% monomer by analytical SEC and SDS-Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation This monoclonal antibody is purified using a multi-step process, including the use of protein A or G to ensure extremely low levels of leachable protein A or aggregates from ascites fluid or culture medium. Storage and Handling This product contains no stabilizing proteins and should be stored at 2-8°C until ready to use. Country of Origin USA Shipping Ships Overnight on Blue Ice Applications and Recommended Usage? Quality Tested by Leinco ELISA Recommended starting range 1:20-1:200 IF Recommended starting range 1:10-1:50 Additional Applications Reported In Literature ? Neutralizes Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Respiratory Syncytial Virus (Clone RSV-96217) is specific for the fusion protein of RSV Types A&B. This antibody is non-reactive with: Influenza A & B, Adenovirus, Para 1-3, Measles, Mumps Background Respiratory syncytial virus (RSV) is a common respiratory virus that infects the majority of children by two years old1, 2. While usually mild, RSV can be serious in infants and older adults and is the leading cause of bronchiolitis and pneumonia in children less than one year of age in the United States1. A related pneumovirus, human metapneumovirus (hMPV), also significantly contributes to hospitalizations resulting from lower respiratory tract infection2. Antibodies have been described that bind and neutralize both RSV and hMPV fusion (F) proteins.
RSV F protein is a type I integral membrane protein that is synthesized as a 574 amino acid inactive precursor, assembled into a trimer, post-translationally modified, then cleaved to produce F1, F2, and intervening peptide pep273. Functional F protein has both pre- and post-fusion conformations. RSV F protein is highly conserved among RSV isolates from both A and B subgroups3 and is the primary target for antiviral drug development3 with several antigenic regions capable of introducing neutralizing antibodies2. RSV and hMPV F protein share ~36% sequence similarity. Research Area Infectious Disease . Seasonal and Respiratory Infections . IVD Raw Material References & Citations1. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases, Link Text
2. Mousa JJ, Binshtein E, Human S, et al. PLoS Pathog. 14(2):e1006837. 2018. 3. McLellan JS, Ray WC, Peeples ME. Curr Top Microbiol Immunol. 372:83-104. 2013. Technical ProtocolsCertificate of Analysis |
Related Products
- -
- -
Prod No. | Description |
---|---|
F653 | |
F655 |
Formats Available
